Correction to: Eye (2010) 24, 1320–1324; doi:10.1038/eye.2010.22; published online 9 April 2010
The marketing authorization holder for bevacizumab (Avastin) was published incorrectly as Novartis in the above-referenced paper. The correct marketing authorization holder is Roche.
The authors would like to apologize for this error.
Additional information
The online version of the original article can be found at 10.1038/eye.2010.22
Rights and permissions
About this article
Cite this article
Chung, YR., Lee, K., Cho, EH. et al. Erratum: Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology. Eye 24, 1736 (2010). https://doi.org/10.1038/eye.2010.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2010.143
